Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Non-Current Debt (2021 - 2025)

Kezar Life Sciences' Non-Current Debt history spans 5 years, with the latest figure at $1.4 million for Q3 2025.

  • For Q3 2025, Non-Current Debt fell 78.36% year-over-year to $1.4 million; the TTM value through Sep 2025 reached $1.4 million, down 78.36%, while the annual FY2024 figure was $5.1 million, 49.24% down from the prior year.
  • Non-Current Debt for Q3 2025 was $1.4 million at Kezar Life Sciences, down from $2.6 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $10.1 million in Q4 2023 and bottomed at $1.4 million in Q3 2025.
  • The 5-year median for Non-Current Debt is $9.6 million (2021), against an average of $7.8 million.
  • The largest annual shift saw Non-Current Debt increased 2.39% in 2023 before it plummeted 78.36% in 2025.
  • A 5-year view of Non-Current Debt shows it stood at $9.6 million in 2021, then increased by 2.2% to $9.8 million in 2022, then increased by 2.39% to $10.1 million in 2023, then crashed by 49.24% to $5.1 million in 2024, then tumbled by 73.12% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Non-Current Debt are $1.4 million (Q3 2025), $2.6 million (Q2 2025), and $3.9 million (Q1 2025).